依达拉奉治疗ATCI患者对血清C反应蛋白和病灶体积的影响

Edaravone treatment in patients with cerebral infarction of atherosclerotic thrombus

目的探讨依达拉奉治疗动脉粥样硬化性血栓性脑梗死(ATCI)患者对血清C反应蛋白(CRP)和病灶体积的影响。方法选择发病48小时内的ATCI患者96例,按性别、年龄、头颅CT病灶体积和部位、临床神经功能缺损程度无明显差异患者进行配对,计48对分治疗组和对照组,治疗组给予依达拉奉注射液30mg静脉滴注,2次/d,共14d,同时给予维脑路通、阿司匹林作为基础治疗;对照组除依达拉奉外,余均同治疗组。采用免疫散射速率比浊法测定96例ATCI患者治疗前及治疗后第5天、第10天、第15天血清CRP浓度,治疗前及第5天、第15天查头颅CT。结果依达拉奉治疗组患者治疗后血清CRP浓度明显低于对照组,差异有显著意义(P<0.05),病灶体积明显小于对照组,差异有显著意义(P<0.05)。结论现有临床证据表明,依达拉奉有降低动脉粥样硬化性血栓性脑梗死患者血清CRP浓度,缩小病灶体积的作用。

Objective To observe the efficacy of edaravone in treatment of patients with cerebral infarction if atherosclerotic throrobus （ATCI）. Methods Ninety six ATCI patients enrolled within 48h of onset were divided into two groups： control group and Edaravone group, 48 patients in each. In treatment group edaravone was infused at a dose of 30 mg, twice a day for 14 days, in addition to hydroxyethylrutin and aspirin as basic treatment. The patients in control group were given the same regime except edaravone. The concentrations of serum CRP in 96 patients were measured by immunoturbidity method before treatment and at 5th,lOth and 15th day after treatment. The head CT scanning was performed, before treatment and at 5th, 15th day after treatment. Results As compared with the controls,the concentration of serum CRP was lower and size of cerebral infarct lesion was reduced significantly. Conclusion Edaravone is effective in decreasing the concentration of serum CRP and deflating cerebral infarct volume of patients with atherosclerotic thrnmbus cerebral infarction.